CONTACT
+91 80 2808 2808
info@biocon.com
Inside banner
Biocon  /  News  /  Company Statements

COMPANY STATEMENTS

2024

EMA’s CHMP recommends approval of Biocon Biologics’ YESINTEK®, biosimilar to J&J’s Stelara®
Dec 15, 2024
Biocon Receives EIR with VAI Status from US FDA for Bengaluru API Facility Site-2
Dec 07, 2024
U.S. FDA Approves Biocon Biologics’ YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
Dec 01, 2024
USFDA Classifies Biocon Biologics’ Biocon Park Site in Bengaluru, India as Voluntary Action Initiated (VAI)
Nov 10, 2024
Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)
Oct 30, 2024
US FDA Completes Inspection at Biocon Biologics’ Insulins Facility at Johor Bahru, Malaysia
Sep 28, 2024
Company Statement on Site 2 – API facility, Bengaluru
Sep 28, 2024
Company Statement on Site 1 – API facility, Bengaluru
Sep 22, 2024
Biocon Pharma Limited Receives US FDA Approval for Sacubitril/Valsartan Tablets
Sep 01, 2024
Biocon Pharma Limited Receives US FDA Approval for Daptomycin Injection ANDA
Aug 30, 2024
Biocon Receives EIR from US FDA for Visakhapatnam API Facility
Aug 30, 2024
Biocon Receives USFDA Establishment Inspection Report with Voluntary Action Indicated for Visakhapatnam Facility
Aug 05, 2024
US FDA Completes Inspection at Biocon Biologics’ Facilities at Biocon Park, Bengaluru, India
July 27, 2024
EMA Approves Biocon Biologics’ New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
June 24, 2024
Company Statement on Site 5 – API facility, Visakhapatnam
June 22, 2024
Company Statement on Site 6 – API facility, Visakhapatnam
Jun 15, 2024
Biocon Receives Approval for Antifungal Medication, Micafungin from US FDA
Jun 03, 2024
Biocon receives approval for Tacrolimus capsules from SAHPRA
Apr 20, 2024
Biocon’s Liraglutide (gSaxenda®) Receive Approval from MHRA
Apr 01, 2024
Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®
Mar 04, 2024
Company Statement on rh-Insulin for Veterinary use
Feb 29, 2024
Company Statement on bBevacizumab
Feb 09, 2024
Biocon Receives Tentative Approval for Dasatinib from the US FDA
Feb 06, 2024

Know more
about us

>> Biocon Biologics
>> Syngene
>> Financial Factsheet

OUR KEY PRIORITIES
Siddharth Mittal
BOARD OF DIRECTORS
KEY THERAPEUTIC AREAS
Arun Chandavarkar
KEY MANAGEMENT TEAM
SHAREHOLDER SERVICES

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2024, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>